Concord Biotech IPO Review – Details, GMP, Price & More
Trade Brains
JULY 31, 2023
A significant amount of the company’s revenue is based on a small number of consumers. As the company has a limited number of customers, it does not have much room to negotiate the prices which are favourable in terms of margins. Concord Biotech IPO Review – GMP The shares of Concord Biotech traded at a premium of 27.6%
Let's personalize your content